Compare ZKH & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ZKH | ENTA |
|---|---|---|
| Founded | 1998 | 1995 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 486.5M | 407.5M |
| IPO Year | 2023 | 2013 |
| Metric | ZKH | ENTA |
|---|---|---|
| Price | $3.20 | $14.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $20.40 |
| AVG Volume (30 Days) | 211.9K | ★ 288.8K |
| Earning Date | 11-20-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,236,195,501.00 | $65,324,000.00 |
| Revenue This Year | $2.44 | $0.99 |
| Revenue Next Year | $9.14 | $0.19 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.50 | $4.09 |
| 52 Week High | $4.03 | $15.34 |
| Indicator | ZKH | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 53.96 | 72.93 |
| Support Level | $2.93 | $11.89 |
| Resistance Level | $3.49 | $14.52 |
| Average True Range (ATR) | 0.18 | 0.86 |
| MACD | 0.02 | 0.10 |
| Stochastic Oscillator | 48.67 | 95.27 |
ZKH Group Ltd engages in providing MRO procurement service platform in China. It provides one-stop MRO procurement and management services for its customers, and offers digital and fulfillment solutions for participants along the industry value chain. It offers a broad range of MRO product offerings covering all MRO product lines on its platform, including spare parts, chemicals, manufacturing parts, general consumables, and office supplies. All of the Group's revenues are derived from the PRC.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.